ALTH Allos Therapeutics, Inc. (MM)

Allos Therapeutics to Hold Q1 2004 Financial Results Conference Call and Webcast on Thursday, May 6 WESTMINSTER, Colo., May 4 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. will hold a conference call Thursday, May 6, 2004, at 11:00 AM EDT to discuss its first quarter 2004 financial results. Time: 11:00 AM EDT Date: Thursday, May 6, 2004 Dial-in: (800) 915-4836 / (973) 317-5319 international Webcast: http://www.allos.com/ (homepage and investor relations section) Interested parties unable to participate in the live conference call may access a recorded rebroadcast by dialing 1-800-428-6051, or +1-973-709-2089 for international callers; the conference ID number is 353018. The replay will be available from 7:00 p.m. ET on Thursday, May 6, 2004 until 11:59 PM ET on May 13, 2004. In addition, the webcast will be archived for on-demand listening for 30 days at http://www.allos.com/. About Allos Therapeutics, Inc. Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drugs for improving cancer treatments. The company's lead clinical candidate, RSR13 (efaproxiral), is a synthetic small molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance the efficacy of standard radiation therapy. In addition, Allos is developing PDX, an injectable small molecule chemotherapeutic agent that has a superior potency and toxicity profile relative to methotrexate and other dihydrofolate reductase, or DHFR, inhibitors. For more information, please visit the company's web site at: http://www.allos.com/. DATASOURCE: Allos Therapeutics CONTACT: Monique M. Greer, VP, Corporate Communications and Investor Relations of Allos Therapeutics, +1-720-540-5241, ; or media, Fern Lazar of Lazar Partners Limited, +1-212-867-1762, , for Allos Therapeutics Web site: http://www.allos.com/

Copyright